Citi raised the firm’s price target on AbbVie (ABBV) to $240 from $205 and keeps a Neutral rating on the shares. The firm adjusted price targets in the biotechnology and pharmaceuticals sector as part of a Q3 earnings preview. The group is well positioned into the second half of 2025 and 2026 as policy overhangs ease and investor focus returns to fundamentals, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie announces FDA approval of updated indication statement for RINVOQ
- AbbVie to present new data from ADC platform at ESMO
- AbbVie price target raised to $284 from $231 at Piper Sandler
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- AbbVie price target raised to $250 from $245 at Cantor Fitzgerald